Aurobindo Pharma Subsidiary Faces USFDA Procedural Observations

The United States Food and Drug Administration (USFDA) recently completed its inspection of a key facility belonging to Apitoria Pharma, a wholly owned subsidiary of Aurobindo Pharma. This assessment, conducted in Andhra Pradesh, concluded with three observations.

Understanding the USFDA Review

The USFDA conducted this inspection at Unit-VI, an Active Pharmaceutical Ingredient (API) manufacturing facility. The review took place from August 24 to August 28, 2026, at E-Bonangi Village, Parawada Mandal, Anakapalli.

• Inspection Duration: 5 days (August 24-28, 2026)
• Observations Noted: 3
• Nature of Observations: Procedural

The three observations identified during the USFDA inspection are described as procedural in nature. This classification suggests issues related to adherence to established operational protocols rather than fundamental product quality or safety concerns.

Aurobindo Pharma’s Operational Scope

Aurobindo Pharma is a pharmaceutical company with extensive operations in manufacturing various products. Its portfolio includes active pharmaceutical ingredients, intermediates, and a range of generic formulations.

• Key Offerings: Astemizole, domeperidone, and omeprazole
• Therapeutic Areas: Anti-infective, oral and sterile antibiotics, pain management, and osteoporosis segments

While the USFDA concluded its review, companies typically address such procedural observations to maintain compliance with regulatory standards. The focus will now be on how Apitoria Pharma and Aurobindo Pharma respond to these findings.